Lantheus Holdings is a leading company in the field of radiopharmaceuticals, focusing on innovative solutions that enhance the ability of clinicians to diagnose and treat diseases. Their core philosophy, encapsulated in the slogan "Find, Fight, Follow®," emphasizes the importance of precision diagnostics and targeted therapies. Over the past 65 years, Lantheus has pioneered advancements in radiopharmaceutical technology, which plays a crucial role in improving patient outcomes. Their products are designed to provide better insights for healthcare professionals, enabling them to make informed decisions that significantly impact patient care.

The company is dedicated to developing next-generation solutions that not only improve diagnostic capabilities but also contribute to the overall effectiveness of treatment strategies. By leveraging advanced radiopharmaceuticals, Lantheus aims to enhance the detection and management of various diseases, ultimately prioritizing patient health and well-being. Their commitment to innovation is evident in their ongoing research and development efforts, which seek to expand the applications of radiopharmaceuticals in clinical practice, thereby making a meaningful difference in the lives of patients.

United States

Lantheus Holdings, Inc. (NASDAQ: LNTH) is the parent company of Lantheus Medical Imaging, Inc. (LMI), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. 

Cancer

Cardiovascular Diseases

Central Nervous System (CNS)

Endocrine System Diseases

Urogenital Diseases

Lantheus Holdings

Prostate cancer

PyL (also known as 18F-DCFPyL) is a fluorinated PSMA-targeted positron emission tomography (PET) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

PYLARIFY (Piflufolastat F 18)

Constipation

Methylnaltrexone is a selective antagonist of opioid binding at the mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting opioid-mediated analgesic effects on the central nervous system.

RELISTOR

Suboptimal echocardiograms

DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension and DEFINITY RT (Perflutren Lipid Microsphere) Injectable Suspension (activated) are ultrasound enhancing agents for use in patients with suboptimal echocardiograms (see Indications and Important Safety Information below and find full Prescribing Information at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.definityimaging.com%2F&amp;esheet=52331593&amp;newsitemid=20201118006059&amp;lan=en-US&amp;anchor=www.definityimaging.com&amp;index=1&amp;md5=66d0551ae70df05ae257d919f2d55b38" rel="nofollow">www.definityimaging.com</a>). DEFINITY and DEFINITY RT are engineered to produce small and consistently sized durable microbubbles to fully evaluate the left ventricle. DEFINITY has extensive safety experience and a consistent safety profile. Since its launch in 2001, more than 14 million echo studies have been performed with DEFINITY, and it is the most prescribed ultrasound enhancing agent in the U.S.

DEFINITY® Room Temperature

Paraganglioma

Pheochromocytoma

Solid tumor/s

AZEDRA is an I 131 labeled iobenguane. Iobenguane is similar in structure to the neurotransmitter norepinephrine (NE) and is subject to the same uptake and accumulation pathways as NE. Iobenguane is taken up by the NE transporter in adrenergic nerve terminals and accumulates in adrenergically innervated tissues, such as the heart, lungs, adrenal medulla, salivary glands, liver, and spleen as well as tumors of neural crest origin. Pheochromocytoma and paraganglioma (PPGL) are tumors of neural crest origin that express high levels of the NE transporter on their cell surfaces. Following intravenous administration, AZEDRA is taken up and accumulates within pheochromocytoma and paraganglioma cells, and radiation resulting from radioactive decay of I 131 causes cell death and tumor necrosis.

AZEDRA® (iobenguane I 131)

Coronary artery disease

Heart disease

Flurpiridaz F 18 injection, a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1)1, was designed to be a novel myocardial perfusion PET imaging agent for the diagnosis of coronary artery disease (CAD). PET imaging with flurpiridaz F 18 has the potential to be a new clinical tool for the evaluation of myocardial perfusion that may better evaluate patients with known or suspected CAD. CAD is the most common form of heart disease, affecting approximately 16.8 million people in the United States. CAD is the leading cause of death in the United States for both men and women. Each year more than half a million Americans die from CAD.

Flurpiridaz F 18

Alzheimer's disease

MK-6240, Novel, late-stage, Tau radiodiagnostic for Alzheimer’s disease

MK-6240 (florquinitau) 

Castration-resistant prostate cancer

PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&amp;T, with the beta-emitting radioisotope no-carrier-added 177Lu.

¹⁷⁷Lu-PNT2002

NAV-4694 (18-flutafuranol)

Glioblastoma

Progenics' small molecule therapeutic candidate 1095 is designed to bind with high affinity to the extracellular domain of prostate specific membrane antigen (PSMA), a protein that is highly expressed in prostate cancer cells. Once bound, 1095 is internalized by the prostate cancer cells, where the beta radiation emitted by iodine-131 kills the malignant cell. This ability to deliver targeted radiation systemically to PSMA expressing cancer cells represents a novel therapeutic mechanism of action to treat prostate cancer. When studied in a compassionate use setting, 1095 markedly reduced PSA and bone pain in a group of heavily pre-treated advanced prostate cancer patients.

1095 (PSMA-targeted iodine-131 labeled small molecule)

¹⁷⁷Lu-DOTA-RM2

Progenics’ molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of &gt;95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with technetium-99m, a gamma-emitter isotope that is widely available, relatively inexpensive, facilitates efficient preparation, and has spectrum characteristics attractive for nuclear medicine imaging applications.

Lantheus Holdings

Company Details